Biotech Values

[vinmantoo]

Efficacy of paxlovid in a large cohort of high risk patients between 4/1/2022 and 2/20/2023 down to 37% (HR for hospitalization or death .63). As a reminder EPIC -HR recruited at the end of 2021 and had 89% efficacy

Thanks dewophile! This reduction would seem to be bullish for ENTA or at least neutral but it is down some $0.70 today. Of course it could be unrelated given as you say the mainstream press hasn't reported much about it. Still, Paxlovid seems to be highly protective against death from Covid.